DENVER — Studies published in a medical journal and presented at a conference showed that tecovirimat did not increase clinical resolution of mpox and may contribute to antiviral resistance for people ...
An international, randomized, double-blind, placebo-controlled Phase III study—the largest of its kind for mpox—found that tecovirimat did not improve clinical outcomes for adults with clade II mpox ...
A new study published in The New England Journal of Medicine revealed that the antiviral drug tecovirimat did not ...
SHELTON, CT / ACCESS Newswire / July 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...
The antiviral drug tecovirimat (Tpoxx) is no better than placebo in achieving a shorter time to clinical resolution, reduced pain, or increased viral DNA clearance in adults infected with clade 2 mpox ...
Mpox (formally Monkeypox) is a viral disease caused by the Monkeypox virus and can infect both humans and animals. Interestingly, this is part of the viral family linked to smallpox. Patients that ...
antiviral effectiveness of the drug in patients. The overall clinical trial will enroll approximately 80 patients. “This is an important milestone towards filing of the clinical trial application and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results